Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.
| Revenue (Most Recent Fiscal Year) | $178.03M |
| Net Income (Most Recent Fiscal Year) | $-70.81M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.75 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -255.12% |
| Net Margin (Trailing 12 Months) | -260.82% |
| Return on Equity (Trailing 12 Months) | -163.73% |
| Return on Assets (Trailing 12 Months) | -75.83% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.52 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.29 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 0.43 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.05 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.11 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.25 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.65 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 265.05M |
| Free Float | 232.08M |
| Market Capitalization | $49.01M |
| Average Volume (Last 20 Days) | 177.88M |
| Beta (Past 60 Months) | 2.49 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 12.44% |
| Percentage Held By Institutions (Latest 13F Reports) | 31.37% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |